What Viatris's FY2025 10-K says: 12 signals
Viatris filed its latest 10-K with the SEC on Feb 26, 2026. It discusses restructuring charge, acquisition completed and competitor named.
Public (VTRS)Pharmaceutical Manufacturing10,000+ employeesviatris.comLinkedIn
- Filed
- Feb 26, 2026
- Period
- FY2025
- Fiscal year end
- 12/31
- Filings
- 1
10-K · latest 9
What Viatris's 10-K filings say
- SEC EDGAR
10-K · FY2025
Filed · Fiscal year ends 12/31 · 12 signals
The company is spending $700M-$850M on a multi-year 'Enterprise-Wide Strategic Review' to optimize its commercial, R&D, and supply chain functions.
$850M
Maximum expected pre-tax charges for restructuring activities
10%
Maximum global workforce reduction
Teva Pharmaceutical Industries Ltd.
Viatris launches major restructuring with $700-850M charge and 10% workforce reduction.
The company is implementing an enterprise-wide strategic review to optimize commercial capabilities, R&D, and supply chain functions, which will incur significant costs.
$850M
Maximum expected pre-tax charges for restructuring activities
10%
Global workforce reduction
technologydata
Viatris targets $600-700M in annual savings from new enterprise-wide strategic review.
As part of a major restructuring, Viatris is aiming for significant cost savings by optimizing its commercial, R&D, and supply chain operations.
$700M
Maximum potential savings from committed restructuring activities once fully implemented
technologydataITML
The company is addressing significant quality and compliance issues at a key manufacturing site, which has already had a negative financial impact ('Indore Impact').
Teva Pharmaceutical Industries Ltd.
Viatris completes multiple major divestitures in 2024 to streamline business and reduce debt.
Viatris completed the sale of its women's healthcare business (Mar 2024), API business in India (Jun 2024), and OTC Business (Jul 2024).
Viatris acquired Aculys Pharma in Oct 2025 to expand its innovative neurology pipeline in Japan.
Viatris acquired Aculys Pharma, a clinical-stage biopharmaceutical company, to gain exclusive rights in Japan for treatments targeting narcolepsy and obstructive sleep apnea.
Viatris targets first-to-market generics for blockbusters Ozempic®, Wegovy™, and Abilify Maintena®.
The company's R&D strategy is focused on being the first to launch generic versions of major drugs like Ozempic®/Wegovy™ (from Novo Nordisk) and Abilify Maintena® (from Otsuka/Lundbeck).
Novo NordiskOtsukaLundbeckDaiichi Sankyo
As a key pillar of its go-forward strategy, Viatris is focused on 'strengthening our technology, data and talent capabilities'.
dataTeva Pharmaceutical Industries Ltd.
Viatris targets global expansion with new drug filings in Canada, Australia, NZ, and Saudi Arabia.
Following the acquisition of rights to sotagliflozin (Inpefa®), Viatris has filed for regulatory approval in multiple international markets outside the U.S.
Showing 9 of 12 filing signals. The Signal API returns all of them.
Get them with one API callSignal API · MCP
Track Viatris with the Signal API
One POST /v1/companies/enrich call with viatris.com returns Viatris 10-K signals (sec-10k), each with its source. Or ask Claude through MCP.
2 credits per signal returned; zero-result calls are free. Endpoint reference
curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"viatris.com","signal_types":["sec-10k"],"limit":20}'Same industry
10-K at related companies
Questions about Viatris 10-K
When did Viatris file its latest 10-K?
What does Viatris's latest 10-K say about restructuring?
Where can I find Viatris's annual report?
Source. Annual reports (Form 10-K) filed with the SEC. Every card links to the filing on EDGAR.
Method. Insights are extracted from the filing text and grouped by category. Numbers are quoted from the filing.
Data as of .